NEW YORK, The multiple sclerosis market in the US will be driven by factors such as strong pipeline.
The market is expected to grow by USD 3.95 bn from 2021 to 2026, progressing at a CAGR of 5.83% during the forecast period, according to Technavio. The report offers an up-to-date analysis as well as exact growth variance and the Y-O-Y growth rate.
Multiple Sclerosis Market in US 2022-2026: Scope
The multiple sclerosis market in US report covers the following areas:
Multiple Sclerosis Market in US size Multiple Sclerosis Market in US trends Multiple Sclerosis Market in US industry analysis
Multiple Sclerosis Market in US 2022-2026: Segmentation
By type, the market has been segmented into biologics and small molecules. The biologics segment will have significant market share growth during the forecast period. Biologics are drugs that are either made of living organisms or have certain components of living organisms, such as proteins, monoclonal antibodies, peptides, genes, and cells.
By route of administration, the market has been segmented into parenteral and oral.
Multiple Sclerosis Market in US 2022-2026: Drivers and Challenges
The strong pipeline is one of the key factors driving the growth of the multiple sclerosis market. Several players are expanding their research to develop new formulations of the existing drugs for multiple sclerosis (MS) due to the significant unmet demand in the market. The high prevalence of the disease, the considerable cost burden on patients, and the lack of effective treatments are encouraging vendors to conduct advanced research on MS to launch better therapeutics in the market to treat the disease.
The high cost of drugs will challenge the multiple sclerosis market during the forecast period. Treatments can help speed up recovery and modify the course of MS and manage symptoms. However, the lifetime cost per MS patient is over USD 4 million. This is the major challenge for the market, which will hamper the growth.
Multiple Sclerosis Market in US 2022-2026: Vendor Analysis
We provide a detailed analysis of around 25 vendors operating in the multiple sclerosis market in the US, including Bayer AG, Biogen Inc., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Johnson and Johnson Inc., Novartis AG, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc. among others.
Multiple Sclerosis Market in US 2022-2026: Key Highlights
CAGR of the market during the forecast period 2022-2026 Detailed information on factors that will assist multiple sclerosis market growth in US during the next five years Estimation of the multiple sclerosis market size in US and its contribution to the parent market Predictions on upcoming trends and changes in consumer behavior The growth of the multiple sclerosis market in US Analysis of the market’s competitive landscape and detailed information on vendors Comprehensive details of factors that will challenge the growth of multiple sclerosis market vendors in US
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
This article was shared with Prittle Prattle News as a Press Release by PRNewswire.
